SEC Form 4/A · accession 0001144204-17-006572

MusclePharm Corp · MSLP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.

Reporting owner

Officer — See Remarks. · Director · 10% Owner

Period of report

Dec 8, 2016

Accepted (ET)

Feb 7, 2017 · 9:00 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001415684

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Dec 8, 2016	A	200,000	$0.00	A	283,434	D
Common Stock^F1	Jan 1, 2017	A	350,000	$0.00	A	633,434	D
Common Stock^F2	holding	—	—		—	1,499,408	I	See Footnote

No Table II lines on this filing.

F1On December 8, 2016, Mr. Drexler was granted 200,000 shares of restricted stock pursuant to the Amended and Restated Executive Employment Agreement between MusclePharm Corporation and Mr. Drexler, dated November 18, 2016 (the "Employment Agreement"). On January 1, 2017, Mr. Drexler was granted 350,000 shares of restricted stock pursuant to the Employment Agreement (the "Second Issuance"). Each grant of restricted stock vests in full upon the first anniversary of its respective grant date. The original Form 4 erroneously reported that the Second Issuance occurred on December 8, 2016. This amendment is being filed to accurately reflect that the Second Issuance occurred on January 1, 2017.
F2Represents shares of common stock held by Consac LLC ("Consac"). Mr. Drexler is the Chief Executive Officer of Consac and may be deemed to be the indirect beneficial owner (as that term is defined under Rule 13d-3 of the Securities Exchange Act) of the common stock that Consac beneficially owns. Mr. Drexler has the power to direct the voting and disposition of the Issuer's common stock that Consac beneficially owns.

President, Chief Executive Officer and Chairman of the Board of Directors.